Navigation Links
Nektar Therapeutics Announces First Quarter 2008 Results
Date:5/7/2008

SAN CARLOS, Calif., May 7 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today the company's financial results for the first quarter ended March 31, 2008.

Cash, cash equivalents, and short-term investments were $412.6 million at March 31, 2008 compared to $482.4 million at December 31, 2007.

Nektar reported a net loss of $40.7 million or $0.44 per share in the first quarter of 2008, compared to a net loss of $25.7 million or $0.28 per share in the first quarter of 2007. The increase in net loss is primarily the result of $4.1 million of expense for maintaining third-party Exubera manufacturing capacity, $5.3 million of expense for our workforce reduction, loss of gross margin associated with Pfizer's termination of the Exubera relationship, as well as significant incremental investment in clinical development programs. Offsetting these expenses are substantial operating efficiencies Nektar has achieved over the last twelve months.

Revenue totaled $20.0 million in the first quarter of 2008 compared to $85.0 million in the first quarter of 2007. This decrease is the result of the termination of Exubera by Pfizer.

"The first quarter was significant for Nektar as it represents the first time that the company has made substantial investment into the clinical development of innovative proprietary drug candidates," said Howard W. Robin, President and Chief Executive Officer. "Today we have moved past inhaled insulin, and our proprietary small molecule PEGylation drug development platform is generating a great deal of industry and scientific interest. We intend to build and advance our impressive pipeline while continuing to exercise financial responsibility."

Mr. Robin will host a confer
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
2. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
3. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
4. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at Merrill Lynch 19th Global Pharmaceutical, Biotechnology & Medical Device Conference in New York City
5. Nektar Announces Agreement With Baxter to Develop New PEGylated Therapeutics for Hemophilia
6. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
7. Nektar Therapeutics Announces Third Quarter 2007 Financial Results
8. Nektar to Announce Third Quarter 2007 Financial Results on Wednesday, November 7, 2007, After the Close of U.S. Financial Markets
9. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
10. Transition Therapeutics to Present at 2008 Morgan Stanley Global Healthcare Unplugged Conference
11. Duska Therapeutics Plans 505(b)(2) NDA Filing Route for ATPace(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... (PRWEB) August 27, 2014 Ellen V. Krieger, ... industry practices recently. The video is meant to describe the ... VA . , With over 28 years of cosmetic and ... work and helps new patients feel welcomed and cared for. ... area for over 28 years, building a solid reputation of ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 DiabetesSisters is ... in collaboration with Diabetes Community Advocacy Foundation (DCAF) as ... 24-25, 2014 at Embassy Suites LAX North. The two ... Meetup featuring DSMA Live”, an event which is open ... October 24th. , Interactive in many ways, DiabetesSisters’ Social ...
(Date:8/27/2014)... 27, 2014 AvePoint, ... compliance software solutions for next-generation social collaboration platforms, ... Inc. 500|5000, an exclusive ranking of the nation’s ... AvePoint joins brands such as Alex and Ani, ... , This underscores continued growth and expansion ...
(Date:8/27/2014)... 2014 BambooIndustry.com is one of the most ... of elegant items for sale now. Recently, it has announced ... As an industry leader, BambooIndustry.com strives to offer one-stop shopping ... products for their houses. Now, it is providing big discounts ... and new clients can enjoy a discounted price (up to ...
(Date:8/27/2014)... August 27, 2014 AttorneyOne.com, a recognized ... the latest information from the FDA on Organic ... August 1, that Organic Raw Carob Powder sold from ... recalled due to possible contamination with Salmonella. , ... weakened immune systems. In healthy people it can cause ...
Breaking Medicine News(10 mins):Health News:Ellen V. Krieger, DDS of McLean, Virginia Announces New Video Describing Industry Best Practices 2Health News:DiabetesSisters and Diabetes Community Advocacy Foundation Join Forces to Bring Together People with Diabetes in Los Angeles 2Health News:DiabetesSisters and Diabetes Community Advocacy Foundation Join Forces to Bring Together People with Diabetes in Los Angeles 3Health News:Inc. Magazine Names AvePoint to the Inc. 500|5000 List of Fastest Growing American Companies for the Fifth Consecutive Year 2Health News:Inc. Magazine Names AvePoint to the Inc. 500|5000 List of Fastest Growing American Companies for the Fifth Consecutive Year 3Health News:Brand New Bamboo Plywoods Now Offered At BambooIndustry.com 2Health News:Organic Raw Carob Powder by Sunburst SuperFoods Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2
... naturally occurring virus that attacks cancer cells but appears to ... possible treatment for malignant, highly aggressive and deadly brain tumors ... few in the United States evaluating this experimental therapy. , ... exposed to the virus in its natural state. It commonly ...
... reported by middle-aged women when their periods change and they ... the April issue of the UK-based Journal of Clinical Nursing. ... USA, spoke to 110 women entering the menopause when ... or shorter intervals. Their average age was 49 and they ...
... in both healthcare and human ... ... the leader in,driving peak performance within Health Information Management (HIM),departments, today ... Resources. She joins Precyse from Pegasus,Communications where she served as Senior ...
... It may produce chemicals that protect the brain, ... -- Regular physical exercise may help protect against ... study. , People with mild cognitive impairment can ... details of conversations, events and upcoming appointments. Most, ...
... Lotus,Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or ... of China,("PRC"), today announced that it will conduct ... Thursday, April 17, 2008 to discuss the fourth ... Zhongyi Liu, Chief Executive Officer and President of ...
... County Washington First in Nation to Embrace the Vending Industry,s ... ... April 16 The nation,s vending industry will,unveil tomorrow a ... Automatic Merchandising Association (NAMA),President Richard M. Geerdes, NCE announced today. ...
Cached Medicine News:Health News:Cedars-Sinai Medical Center opens patient trial of virus that attacks brain cancer cells 2Health News:Getting a good night's sleep is the biggest problem for women entering the menopause 2Health News:Getting a good night's sleep is the biggest problem for women entering the menopause 3Health News:Precyse Solutions Appoints Karen Heisler as New Corporate Vice President, Human Resources 2Health News:Exercise Could Cut Risk of Mild Cognitive Impairment 2Health News:Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results 2Health News:Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results 3Health News:Nation's Vending Industry Unveils New Health Oriented Vending Program: 2Health News:Nation's Vending Industry Unveils New Health Oriented Vending Program: 3Health News:Nation's Vending Industry Unveils New Health Oriented Vending Program: 4
(Date:8/26/2014)... --  Quanta Aesthetic Lasers , the premier emerging energy-based aesthetic ... the offerings in their robust product portfolio with the addition ... shipping to medical spas, clinics, and doctors, offices in ... is manufactured in the Chianti hills of Florence, ... was previously sold as both the VASERShape™ and MC1, but ...
(Date:8/26/2014)... MONTREAL , Aug. 26, 2014  When it comes ... very little clinical relevance. But Timesulin happens to answer ... of insulin disposable pen on the market, Timesulin shows ... advantage being, indeed, preventing from missed or double insulin ... it is put back on the insulin pen after ...
(Date:8/26/2014)... , August 26, 2014 Equashield ... Transfer Devices (CSTDs) for hazardous drugs, announced today it ... top nurses from around the United States ... strategies to increase nurses, awareness of issues around occupational ... safety, and closed systems for hazardous drug transfer. ...
Breaking Medicine Technology:Another Italian Beauty Joins the Quanta Aesthetic Lasers Lineup 2Montméd obtains reimbursement of Timesulin, the smart insulin pen timer cap, by major insurance companies in Canada 2Equashield Appoints Nurse Advisory Council 2Equashield Appoints Nurse Advisory Council 3Equashield Appoints Nurse Advisory Council 4
... Epocal, Inc., a leading edge provider of point of ... and Drug Administration (FDA) clearance to market its new lactate ... the epoc System are used to evaluate acid-base status and ... of the blood).  The addition of lactate to the epoc ...
... , ANN ARBOR, Mich. , June 15 ... announced that its wholly-owned CLIA-certified clinical testing subsidiary, HartLab, ... a full array of microbiology testing.  Adeona believes that ... HartLab,s revenues in the current quarter and beyond and ...
Cached Medicine Technology:Epocal Announces FDA Clearance of Lactate Test 2Adeona Announces HartLab Expansion Into Microbiology Testing Services 2Adeona Announces HartLab Expansion Into Microbiology Testing Services 3Adeona Announces HartLab Expansion Into Microbiology Testing Services 4Adeona Announces HartLab Expansion Into Microbiology Testing Services 5
The Tele-Pro WEP-4200 Telemetry System is an 8-Patient Stand Alone System. Offering capabilities such as arrhythmia analysis, trends and full disclosure, the Tele-Pro is a system to help hospitals to...
ISI DuraHand is the reusable, easy to sterilize surgical hand immobilizer....
... DataPro is a smart, sophisticated and compact medium ... cost effective chemistry analyser in its class! It ... do 230 tests per hour. The DataPro runs ... a normal biochemistry laboratory and runs a wide ...
MagaCell-Streptavidin is a streptavidin coupled to magnetizable cellulose/iron oxide particles...
Medicine Products: